Donaldson Company has reported its August 27 results into a market where the extraordinary pre-print anxiety has already dissolved — the question now is what the numbers mean for a stock that has rebounded cleanly from recent lows.
The options positioning that defined the lead-up to this print has collapsed back to normal. The put/call ratio closed August 26 at 0.57, well below its 20-day average of 0.99 — a sharp reversal from the 5.73 reading on August 25 that marked the highest defensive hedging the stock had seen all year. That spike was a one-session event: put buyers loaded up ahead of the release, and those positions have now either expired, been closed, or been neutralized by the print itself. The stock has responded positively, rising 2.1% on August 26 to $95.24, and is up about 2.6% on the week. The pre-earnings fear did not translate into a sell-off.
Short interest reinforces the cleaner picture. Bears retreated sharply in the days around the print — SI fell 17% in a single session on August 25 to 2.2% of the free float, extending a month-long unwind that has now shed roughly 38% of short positions from their July levels. The borrow market is loose: availability is running at 2,582%, meaning there are far more shares available to lend than are currently borrowed. Cost to borrow has edged up about 33% on the week to 0.51%, but remains trivially low in absolute terms. The ORTEX short score has also declined steadily, from 43.6 on August 17 to 34.3 — moving away from short-pressure territory.
The analyst debate heading into the print centres on the durability of Donaldson's growth mix. Bulls point to the Life Sciences division, which grew 13.1% in fiscal 2025, and to management's expectation of margin expansion through pricing and operating efficiency. Baird raised its target to $105 from $95 just before the print, maintaining its Outperform rating — a signal of conviction ahead of the release. Bears focus on the cyclical drag: Aerospace and Defense faces a tougher comparison after record fiscal 2025 levels, and the mobile end markets — construction, mining, agriculture — remain exposed to capital expenditure caution. Morgan Stanley holds an Equal-Weight with a $91 target, below the current price. The mean analyst target of $98.80 implies modest upside from the post-print level.
The print itself will test whether Life Sciences momentum and margin delivery are enough to offset the cyclical softness in mobile markets — and whether the Baird upgrade to $105 or the Morgan Stanley caution at $91 better reflects what the numbers actually say.
See the live data behind this article on ORTEX.
Open DCI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
